@article{8684376,
  abstract     = {{Exogenous glucocorticoids are widely used in the clinic for the treatment of inflammatory disorders and hematological cancers. Unfortunately, their use is associated with debilitating side effects, including hyperglycemia, osteoporosis, mood swings, and weight gain. Despite the continued efforts of pharma as well as academia, the search for so-called selective glucocorticoid receptor modulators (SEGRMs), compounds with strong anti-inflammatory or anti-cancer properties but a reduced number or level of side effects, has had limited success so far. Although monoclonal antibody therapies have been successfully introduced for the treatment of certain disorders (such as anti-TNF for rheumatoid arthritis), glucocorticoids remain the first-in-line option for many other chronic diseases including asthma, multiple sclerosis, and multiple myeloma. This perspective offers our opinion on why a continued search for SEGRMs remains highly relevant in an era where small molecules are sometimes unrightfully considered old-fashioned. Besides a discussion on which bottlenecks and pitfalls might have been overlooked in the past, we elaborate on potential solutions and recent developments that may push future research in the right direction.}},
  articleno    = {{559673}},
  author       = {{Van Moortel, Laura and Gevaert, Kris and De Bosscher, Karolien}},
  issn         = {{1664-2392}},
  journal      = {{FRONTIERS IN ENDOCRINOLOGY}},
  keywords     = {{glucocorticoids,glucocorticoid receptor,selective GR modulators,drug discovery,inflammation,assay development,GR,SEGRM,MULTIPLE-SCLEROSIS,INHALED CORTICOSTEROIDS,TOPICAL CORTICOSTEROIDS,DNA-BINDING,AGONIST,MAPRACORAT,EFFICACY,MECHANISMS,MODULATORS,DISCOVERY}},
  language     = {{eng}},
  pages        = {{11}},
  title        = {{Improved glucocorticoid receptor ligands : fantastic beasts, but how to find them?}},
  url          = {{http://doi.org/10.3389/fendo.2020.559673}},
  volume       = {{11}},
  year         = {{2020}},
}

Altmetric

View in Altmetric

Web of Science

Times cited: